Bio-Connect

Anti-CD7 [TH69]

Research Use Only
Ab03054-10.0
Absolute Antibody
ApplicationsFlow Cytometry, Neutralisation/Blocking
Product group Antibodies
ReactivityHuman
TargetCD7
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Absolute Antibody
  • Product Name
    Anti-CD7 [TH69]
  • Delivery Days Customer
    7
  • Antibody Specificity
    This antibody binds the extracellular domain of human CD7. CD7 is expressed on the majority of immature and mature T-lymphocytes, and T cell leukemia. It is also found on natural killer cells, a small subpopulation of normal B cells and on malignant B cel
  • Application Supplier Note
    The therapeutic application of this antibody was explored to determine its potential use in the treatment of Human T-cell acute lymphocytic leukemia (ALL). When nude mice bearing approx. 2 g of tumor were treated with a single injection of CD7 antibody TH-69, 82.6% reached complete remission within 10 d whereas 13.0% showed partial remission. (PMID: 8904888). This antibody was also used in the development of a recombinant immunotoxin by linking the scFv version of this antibody to a truncated Pseudomonas exotoxin A fragment containing the catalytic domains II and III but lacking the receptor binding domain I. Approximately 20% of leukemic cells from a patient with CD7-positive acute T-cell leukemia kept in long-term primary culture for 30 cell generations were killed within 96 h after treatment with the toxin (PMID: 12019163). This antibody was also used in the generation of a fusion protein scFvCD7:sFasL, that is designed to have leukemia-restricted activity. wherein the scFv version of this antibody is genetically linked to soluble homotrimeric FasL. Treatment of T-cell acute lymphoblastic leukemia (T-ALL) cell lines and patient-derived T-ALL, peripheral T-cell lymphoma (PTCL), and CD7-positive acute myeloid leukemia (AML) cells with homotrimeric scFvCD7:sFasL revealed potent CD7-restricted induction of apoptosis that was augmented by conventional drugs, farnesyl transferase inhibitor L-744832, and the proteasome inhibitor bortezomib (PMID: 16332967).
  • Applications
    Flow Cytometry, Neutralisation/Blocking
  • Applications Supplier
    FC; block;
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    TH69
  • Gene ID924
  • Target name
    CD7
  • Target description
    CD7 molecule
  • Target synonyms
    CD7 antigen (p41); GP40; LEU-9; p41 protein; T-cell antigen CD7; T-cell leukemia antigen; T-cell surface antigen Leu-9; Tp40; TP41
  • Host
    Human
  • Isotype
    IgG1
  • Protein IDP09564
  • Protein Name
    T-cell antigen CD7
  • Scientific Description
    This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.
  • Reactivity
    Human
  • Reactivity Supplier
    Human
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203